Join to view full profile
55 Fruit StBoston, MA 02114
Phone+1 617-724-4000
Dr. Barnes is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2005 - 2007
University of Illinois College of MedicineClass of 2004
Certifications & Licensure
MA State Medical License 2007 - 2028
NH State Medical License 2024 - 2024
ME State Medical License 2020 - 2021
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2012, 2014, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2017
Clinical Trials
Publications & Presentations
PubMed
- Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.Jacob D Soumerai, Meghan C Thompson, Ahmet Dogan, Venkatraman E Seshan, Kelsey Flaherty
Blood Advances. 2026-06-30 - 1 citationsLenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.Nicolas Gower, Pierre Feugier, Jason Westin, Jean-Marc Schiano De Colella, Hervé Tilly
Blood. 2026-06-18 - Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium.Colin J Thomas, Min Jung Koh, Omar Elghawy, Jessy Xinyi Han, Leora Boussi
Leukemia & Lymphoma. 2026-05-01
Abstracts/Posters
- Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD EvaluationJeffrey A. Barnes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)Jeffrey A. Barnes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: